Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma

M. Saijo, K. Nakamura, Naoyuki Ida, Atsuko Nasu, T. Yoshino, H. Masuyama, H. Yanai
{"title":"Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma","authors":"M. Saijo, K. Nakamura, Naoyuki Ida, Atsuko Nasu, T. Yoshino, H. Masuyama, H. Yanai","doi":"10.1097/PAS.0000000000001353","DOIUrl":null,"url":null,"abstract":"Endometrial carcinosarcoma (ECS) is a rare and aggressive mixed-type epithelial and mesenchymal tumor. This study focused on the histologic appearance, loss of DNA mismatch repair (MMR) protein expression, and aberrant p53 expression in the epithelial component, and overall prognosis of 57 cases with ECS. Histologically, 21 and 36 cases exhibited low-grade (endometrioid grade 1 and 2) and high-grade (others) epithelial components, respectively. In a Kaplan-Meier analysis, patients with a high-grade epithelial component exhibited worse progression-free survival (PFS), compared with those with a low-grade component. Although the former group also exhibited worse overall survival, the difference was not significant. Thirty-six cases exhibited aberrant p53 expression. Of these, 5 cases exhibited focally aberrant p53 expression in carcinomatous components with diffuse aberrant p53 expression in mesenchymal components. Aberrant expression of p53 did not show significant association with prognosis. Six patients with MMR deficiency exhibited relatively better PFS. In conclusion, a low-grade epithelial component is a superior predictor of the PFS of ECS, compared with MMR protein and p53 expression status. In some cases of ECS, TP53 mutation may be a late event associated with histogenesis of the sarcomatous component.","PeriodicalId":275221,"journal":{"name":"The American Journal of Surgical Pathology","volume":"218 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Surgical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PAS.0000000000001353","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

Endometrial carcinosarcoma (ECS) is a rare and aggressive mixed-type epithelial and mesenchymal tumor. This study focused on the histologic appearance, loss of DNA mismatch repair (MMR) protein expression, and aberrant p53 expression in the epithelial component, and overall prognosis of 57 cases with ECS. Histologically, 21 and 36 cases exhibited low-grade (endometrioid grade 1 and 2) and high-grade (others) epithelial components, respectively. In a Kaplan-Meier analysis, patients with a high-grade epithelial component exhibited worse progression-free survival (PFS), compared with those with a low-grade component. Although the former group also exhibited worse overall survival, the difference was not significant. Thirty-six cases exhibited aberrant p53 expression. Of these, 5 cases exhibited focally aberrant p53 expression in carcinomatous components with diffuse aberrant p53 expression in mesenchymal components. Aberrant expression of p53 did not show significant association with prognosis. Six patients with MMR deficiency exhibited relatively better PFS. In conclusion, a low-grade epithelial component is a superior predictor of the PFS of ECS, compared with MMR protein and p53 expression status. In some cases of ECS, TP53 mutation may be a late event associated with histogenesis of the sarcomatous component.
子宫内膜癌肉瘤DNA错配修复蛋白和p53的组织学表现和免疫组化
子宫内膜癌肉瘤(ECS)是一种罕见的侵袭性上皮和间充质混合型肿瘤。本研究主要关注57例ECS的组织学外观、DNA错配修复(DNA mismatch repair, MMR)蛋白表达缺失、上皮成分中p53表达异常以及总体预后。组织学上,21例和36例分别表现为低级别(子宫内膜样1级和2级)和高级别(其他)上皮成分。在Kaplan-Meier分析中,与具有低级别上皮成分的患者相比,具有高级别上皮成分的患者表现出更差的无进展生存(PFS)。尽管前一组也表现出更差的总体存活率,但差异并不显著。36例出现p53异常表达。其中,5例癌组织中p53表达局部异常,间质组织中p53表达弥漫性异常。p53的异常表达与预后无显著相关性。6例MMR缺乏患者表现出相对较好的PFS。总之,与MMR蛋白和p53表达状态相比,低级别上皮成分是ECS PFS的更好预测因子。在一些ECS病例中,TP53突变可能是与肉瘤成分的组织发生相关的晚期事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信